HKSTP Leads Hong Kong Life and Health Tech Delegation to Go Global at MEDICA 2026

Hong Kong — As the global healthcare industry prepares for MEDICA 2026—the world’s premier medtech  trade fair held in Düsseldorf, Germany from November 16 to 19—Hong Kong is stepping into the spotlight. In a historic first, the Hong Kong Science and Technology Parks Corporation (HKSTP) is leading the inaugural technology delegation to the prestigious event.

Partnering with the Hong Kong Trade Development Council (HKTDC), HKSTP is guiding 22 top-tier local life and health technology enterprises and university partners to the exhibition. Operating out of the dedicated "Hong Kong Pavilion" and major exhibition zones, the delegation is set to present a comprehensive array of world’s first breakthrough medical solutions.

These homegrown innovations span five critical domains: minimally invasive and surgical robotics, advanced orthopedic implants and biomaterials, ophthalmic surgery and vision care, cancer early screening, and non-invasive health management and monitoring. The mission is clear: to actively expand into the European market and consolidate Hong Kong’s leading position as an international hub for life and health innovation.

Eyebright Medical: Scaling Global Heights from a Hong Kong Base

A prime example of the formidable technological strength joining the delegation is Eyebright Medical, an established, innovation-driven enterprise with a rapidly expanding global footprint. Having set up its global headquarters in Hong Kong Science Park in early 2024, the company is using the city as a strategic springboard for its internationalization.

Already enjoying long-term commercial traction in core European markets including Germany, France, Italy, and Switzerland, Eyebright is heading to MEDICA 2026 with a robust, MDR-certified product portfolio.

"Our core objective at MEDICA is to showcase our latest ophthalmic innovations alongside our newly integrated Delta Medical sports medicine business," explains Ms. Zhou Yuxi, General Manager of Eyebright Medical (Hong Kong). "Direct engagement with clinical professionals on this international platform allows us to validate our product strength, gather first-hand clinical feedback, and efficiently connect with European partners."

Eyebright will feature its advanced intraocular lenses (IOLs). On display are the MDR-certified All Range® extended depth of focus IOL and Max Vision® full-range multifocal IOL. All Range® adopts a diffraction-free, non-segmented optical structure to deliver continuous clear far and intermediate vision and improve near vision. Max Vision® combines diffractive multifocal technology with EDOF design. It delivers sufficient, continuous full-range vision for patients, with scientifically modulated light energy distribution to reduce visual disturbance. Both IOLs are crafted from hydrophobic acrylic material with near-zero glistenings and feature a preloaded design.

By leveraging China's "engineer talent dividend" and massive manufacturing capabilities, Eyebright delivers R&D that rivals developed nations but with premium-quality products. "Attending with the HKSTP delegation is a game-changer," Ms. Zhou adds. "It provides incredible endorsement, boosts our international image, and allows us to share business resources with other cutting-edge Hong Kong startups while demonstrating the city’s overall I&T ecosystem strength."

Agilis Robotics: Disrupting Surgery with Flexible Innovation

Also representing Hong Kong's deep tech capabilities at MEDICA is Agilis Robotics, a university spin-off incubated by HKSTP. The company is preparing to introduce Europe to a medical marvel: a highly flexible, miniaturized robotic system designed specifically for minimally invasive surgeries via natural orifices, such as the urinary and digestive tracts.

Historically, removing tumors as a whole (en bloc resection) from tight natural orifices has been exceptionally difficult, requiring a level of manual dexterity that few surgeons possess. Removing tumours in fragments often leads to higher cancer recurrence rates. Agilis Robotics solves this by equipping standard endoscopes with tiny, 2.8-3.5mm robotic "hands".

"Our product provides a pair of hands with dexterous operational freedom inside the body," says Prof. Ka-Wai Kwok, Co-Founder and Director of Agilis Robotics. "Doctors can use their existing endoscopes, meaning we aren't forcing them to completely overhaul their surgical habits. We are aiming to significantly lower the learning curve so more doctors can perform these life-saving single-piece resections. In fact, training for medical professionals with this robotic system can take as little as approximately 2 hours."

Having successfully completed a global first human clinical case with their system in December 2024 for en-bloc bladder tumour resection (ERBT), Agilis is currently advancing through FDA and NMPA clinical phases. At MEDICA, their goal is to connect with pioneering European users to prepare for the crucial CE mark process.

"We want to break the stereotype that medical robots must be massive and prohibitively expensive," Prof. Kwok notes. " By adapting to existing endoscope platforms, our robotic system could drastically lower hospital costs. HKSTP’s Incu-Bio program was instrumental in getting us here—providing the lab space and investor exposure needed to transition from academic research to actual production. Now, they are helping us showcase our capabilities on the global stage."

HKSTP: The Ecosystem Orchestrator Powering Global Expansion

The breakthroughs demonstrated by Eyebright Medical and Agilis Robotics are not isolated successes; they are the direct result of a meticulously cultivated ecosystem. As Hong Kong's innovation flagship, HKSTP has successfully gathered over 400 life and health technology companies.

Expanding a biotech or medtech startup overseas is notoriously challenging. HKSTP bridges the gap by transforming leading conceptual ideas into practical, commercialized outcomes. The Corporation's robust ecosystem supports enterprises throughout their entire innovation journey, providing critical resources including:

Capital and Investment: Connecting startups with the funding required to navigate lengthy clinical and regulatory pathways.

Top-Tier Talent: Offering access to a deep, specialized pool of researchers and engineers.

World-Class Infrastructure: Providing advanced laboratories, cleanrooms, and R&D facilities to ensure products meet global standards.

Market Channels: Organizing prominent international delegations, like the upcoming trip to MEDICA, to facilitate direct market access and exposure.

As the MEDICA 2026 exhibition doors open this November, the HKSTP-led delegation is poised to prove that Hong Kong is not just a participant in the global life and health technology sector, but a driving force shaping its future.